Controversies about the treatment of myasthenia gravis.
Open Access
- 1 July 1980
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 43 (7) , 644-659
- https://doi.org/10.1136/jnnp.43.7.644
Abstract
Clinicians treating patients with myasthenia gravis must choose cholinergic drugs, corticosteroids, immunosuppressive drugs, thymectomy, or plasmapheresis. Clinicians must decide the sequence or combination of these therapies and when to deem lack of improvement a sign for a different therapeutic approach. Because controlled trials have not been done to evaluate therapies that may require months or years before benefit is evident, controversy abounds.Keywords
This publication has 125 references indexed in Scilit:
- Evaluation of Medical PracticesNew England Journal of Medicine, 1979
- Clinical Research in General Medical JournalsNew England Journal of Medicine, 1979
- Immune complexes in myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 1979
- Myasthenia GravisNew England Journal of Medicine, 1978
- Myasthenia GravisNew England Journal of Medicine, 1978
- Plasmapheresis and Immunosuppressive Drug Therapy in Myasthenia GravisNew England Journal of Medicine, 1977
- Renal Clearance of Pyridostigmine in Patients with Myasthenia gravisEuropean Neurology, 1977
- Myasthenia gravis: clinical and histological features in relation to thymectomy.Journal of Neurology, Neurosurgery & Psychiatry, 1976
- Studies in myasthenia gravis: Effects of thymectomy: Results on 185 patients with nonthymomatous and thymomatous myasthenia gravis, 1941–1969The American Journal of Medicine, 1971
- Tumours of the thyroid gland in relation to some general concepts of neoplasiaJournal of the Faculty of Radiologists, 1959